Company Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization.
NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
| Country | United States |
| Founded | 2001 |
| IPO Date | Nov 2, 1999 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,100 |
| CEO | Christopher Michael Smith BSc |
Contact Details
Address: 9490 Neogenomics Way Fort Myers, Florida 33912 United States | |
| Phone | (239) 768-0600 |
| Website | neogenomics.com |
Stock Details
| Ticker Symbol | NEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001077183 |
| CUSIP Number | 64049M209 |
| ISIN Number | US64049M2098 |
| Employer ID | 74-2897368 |
| SIC Code | 8734 |
Key Executives
| Name | Position |
|---|---|
| Christopher Michael Smith BSc | Chief Executive Officer and Director |
| Jeffrey S. Sherman M.B.A. | Chief Financial Officer |
| Vishal Sikri | President of Advanced Diagnostics |
| Melody Harris Esq., J.D. | President of Enterprise Operations |
| Warren Stone | President of Clinical Services |
| Gregory D. Aunan | Chief Accounting Officer |
| Kendra Sweeney | Vice President of Investor Relations and Communications |
| Alicia Olivo | Executive Vice President of Business Development, General Counsel and Corporate Secretary |
| Hutan Hashemi J.D. | Chief Compliance Officer |
| Dr. Derek Lyle M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 8, 2024 | ARS | Filing |
| Apr 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2024 | 144 | Filing |
| Feb 26, 2024 | 8-K/A | [Amend] Current report |
| Feb 23, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 144 | Filing |